多西他赛联合顺铂和替吉奥胶囊治疗宫颈癌的临床疗效观察

目的 研究多西他赛联合顺铂和替吉奥胶囊治疗宫颈癌的临床疗效和安全性。方法 将2011年1月-2013年12月就诊于重庆市大足区人民医院的宫颈癌患者120例随机分为联合治疗、多西他赛、替吉奥胶囊组，每组40例，3组患者均在1个疗程的前3天每天静脉滴注注射用顺铂30 mg/m²，联合治疗组在此基础上在第1天静脉滴注多西他赛注射液，60 mg/m²，同时口服替吉奥胶囊60 mg/m²，2次/d，连服2周。多西他赛组静脉滴注多西他赛注射液，用法用量同联合治疗组。替吉奥胶囊组口服替吉奥胶囊，用法用量同治疗组。21 d为一个疗程，3组患者共治疗2个疗程。比较3组患者治疗后的临床疗效、肿瘤直径和不良反应发生情况。结果 治疗后3组患者的肿瘤直径均显著减小，同组治疗前后差异有统计学意义（P<0.05、0.01）；治疗后，多西他赛组和替吉奥胶囊组患者肿瘤直径较联合治疗组大，差异有统计学意义（P<0.05）。联合治疗组、多西他赛组和替吉奥胶囊组的总有效率分别为95.0%、77.5%、80.0%，后两组的总有效率均显著低于联合治疗组，差异有统计学意义（P<0.05）。3组患者均发生化疗的毒副反应，发生率为100%，其中主要包括恶心、呕吐、腹泻、脱发、肾功能损伤、骨髓抑制。3组患者不良反应发生率差异无统计学意义。结论 多西他赛联合顺铂和替吉奥胶囊治疗宫颈癌具有良好的临床疗效，可显著减小肿瘤直径，且不良反应可控。

Observation of clinical efficacy of docetaxel combined with cisplatin and Gimeracil Capsule in the treatment of cervical cancer

Objective To investigate the efficacy and safety of docetaxel combined with cisplatin and Gimeracil Capsule in the treatment of cervical cancer. Methods Cervical cancer patients (120 cases) who came to the People's Hospital of Dazu Country from January 2011 to December 2013 were randomly divided into combined treatment, docetaxel, and Gimeracil Capsule groups (n=40). The patients in three groups were given cisplatin for iv injection (30 mg/m²) on the first three days of one course. The patients in the combined treatment group were iv administered with Docetaxel Injection (60 mg/m²), and at the same time, they were po administered with Gimeracil Capsule (60 mg/m²), twice daily for two weeks. The patients in the docetaxel group were iv administered with Docetaxel Injection, and the usage and dosage were the same as those in the combined treatment group. The patients in the Gimeracil Capsule group were po administered with Gimeracil Capsules, and the usage and dosage were the same as those in the combined treatment group. One course was 21 d in three groups and all the patients accepted the treatment for two courses. The clinical efficacy, tumor diameter, and adverse reaction of chemotherapy in three groups were compared. Results After treatment, tumor diameter in three groups were significantly decreased, and the difference was statically significant in the same group before and after treatment (P < 0.05, 0.01). After treatment, tumor diameters in docetaxel and Gimeracil Capsule groups were larger than that in the combined treatment group, with significant difference (P < 0.05). The total effective rates of combined treatment, docetaxel, and Gimeracil Capsule groups were 95.0%, 77.5%, and 80.0%, respectively, and the total effective rate of the last two groups were significantly lower than that in the combined treatment group, with significant difference (P < 0.05). There were side reactions of chemotherapy in three groups, and the incidence was 100%, which mainly included nausea, vomiting, diarrhea, hair loss, kidney damage, and bone marrow suppression. There was no statistically significant difference in the incidence of adverse reactions in three groups. Comclusion Docetaxel combined with cisplatin and Gimeracil Capsule has a good clinical efficacy in the treatment of cervical cancer, which can significantly reduce the tumor diameter and the adverse reactions are under control.